On June 16, 2025, FibroBiologics, Inc. announced the completion of a $5 million third tranche under a Standby Equity Purchase Agreement with YA II PN, Ltd., increasing their total funding to $15 million. The funds are secured through convertible promissory notes with specific conversion prices tied to the company's stock performance.